Article

Altering Sequence of Cannabinoids, Chemotherapy Administration Improves Anticancer Effects

Sequence of drug administration is crucial to the success of combination treatments for cancer using cannabinoids.

The sequential use of chemotherapy and cannabinoids more effectively kills cancer than chemotherapy alone, new findings suggest.

Cannabinoids are active chemicals in cannabis, that when extracted and purified, have demonstrated anticancer properties, particularly in certain brain cancers.

In a study published in the International Journal of Oncology, investigators sought to examine the effect of pairing cannabinoids and their anticancer activity in cell line models.

The investigators tested different combinations of cannabinoids against leukemia cells in the lab, to determine whether existing chemotherapy treatments worked successfully alongside the cannabinoids. They also sought to determine whether using the drugs in a different order had any impact.

The results of the study showed that the sequential use of an initial dose of chemotherapy first followed by cannabinoids significantly improved overall results against the cancer cells. Furthermore, several cannabinoids could be paired together to generate a superior effect to chemotherapy alone, according to the authors.

“The sequence of chemotherapy results in greater induction of apoptosis, which this was the opposite when the schedule of administration was reversed,” the authors wrote.

The findings suggest that a similar effect could be achieved with a lower dose of chemotherapy. If it could be translated to clinical use in humans, it would result in fewer and less severe chemotherapy-induced adverse events.

“We have shown for the first time that the order in which cannabinoids and chemotherapy are used is crucial in determining the overall effectiveness of this treatment,” said lead investigator Dr Wai Liu. “These extracts are highly concentrated and purified, so smoking marijuana will not have a similar effect. But cannabinoids are a very existing prospect in oncology, and studies such as ours serve to establish the best ways that they should be used to maximize a therapeutic effect.”

Other compounds may lessen adverse events resulting from chemotherapy in the G-quadruplex, which is considered an emerging therapeutic target in oncology because of its key role in DNA replication and translation.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards